Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mangoceuticals (MGRX) EBITDA Margin (2023 - 2025)

Historic EBITDA Margin for Mangoceuticals (MGRX) over the last 3 years, with Q3 2025 value amounting to 8953.45%.

  • Mangoceuticals' EBITDA Margin fell 76352400.0% to 8953.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 4142.63%, marking a year-over-year decrease of 29688000.0%. This contributed to the annual value of 1294.42% for FY2024, which is 341400.0% down from last year.
  • Per Mangoceuticals' latest filing, its EBITDA Margin stood at 8953.45% for Q3 2025, which was down 76352400.0% from 3133.98% recorded in Q2 2025.
  • In the past 5 years, Mangoceuticals' EBITDA Margin registered a high of 733.99% during Q3 2023, and its lowest value of 8953.45% during Q3 2025.
  • Its 3-year average for EBITDA Margin is 2529.39%, with a median of 1594.02% in 2024.
  • Its EBITDA Margin has fluctuated over the past 5 years, first soared by 14349100bps in 2024, then plummeted by -76352400bps in 2025.
  • Mangoceuticals' EBITDA Margin (Quarter) stood at 1050.87% in 2023, then crashed by -52bps to 1594.02% in 2024, then tumbled by -462bps to 8953.45% in 2025.
  • Its EBITDA Margin was 8953.45% in Q3 2025, compared to 3133.98% in Q2 2025 and 4440.0% in Q1 2025.